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In the past several years, a number of cellular proteins have been identified as candidate entry receptors for
hepatitis C virus (HCV) by using surrogate models of HCV infection. Among these, the tetraspanin CD81 and
scavenger receptor B type I (SR-BI), both of which localize to specialized plasma membrane domains enriched
in cholesterol, have been suggested to be key players in HCV entry. In the current study, we used a recently
developed in vitro HCV infection system to demonstrate that both CD81 and SR-BI are required for authentic
HCV infection in vitro, that they function cooperatively to initiate HCV infection, and that CD81-mediated
HCV entry is, in part, dependent on membrane cholesterol.
Hepatitis C virus (HCV) is a member of the Flaviviridae
family of viruses and is a major cause of chronic hepatitis
and hepatocellular carcinoma (3, 15). The HCV genome is
a positive-strand "9.6-kb RNA molecule consisting of a
single open reading frame which is flanked by 5# and 3#
untranslated regions (UTR). The HCV 5# UTR contains a
highly structured internal ribosome entry site (14, 50, 64, 78,
79, 86), while the 3# UTR is essential for replication (32, 88).
The HCV open reading frame encodes a single polyprotein
of 3,008 to 3,037 amino acids in length that is posttransla-
tionally processed by host and viral proteases to produce at
least 10 different proteins: core protein, envelope proteins
E1 and E2, p7, and nonstructural proteins NS2, NS3, NS4A,
NS4B, NS5A, and NS5B (6, 15, 64).
The host-virus interactions required during the initial steps
of HCV infection are not completely understood. Prior to the
development of an in vitro infectious HCV system, HCV
pseudotyped retroviral particles (HCVpp), which comprise a
reporter retrovirus enclosed in an envelope containing HCV
glycoproteins E1 and E2, have allowed detailed analyses of the
host-virus interactions required for HCVpp entry (9, 10, 16, 30,
31, 34, 39, 46, 81, 83). Using a combination of HCVpp and
recombinant soluble E2 glycoprotein (sE2) binding assays, a
number of cellular proteins have been identified as potential
candidates for HCV entry receptors, including the tetraspanin
protein CD81 (61), scavenger receptor B type I (SR-BI) (68),
which is a cellular protein that binds high-density lipoprotein
(HDL), the low-density lipoprotein receptor (LDL-R) (1, 52),
the C-type lectins L-SIGN and DC-SIGN (25, 33, 48, 62),
heparin sulfate (8), and the asialoglycoprotein receptor (67).
The roles of CD81 and SR-BI as HCVpp receptors are well
documented (2, 7, 9, 11, 39, 68, 91), and CD81 was recently
shown to be required for cell culture-derived HCV infection
(47, 85, 89, 92). However, the extent to which SR-BI is re-
quired for HCV infection and whether it functions coopera-
tively with CD81 are poorly understood.
Cellular cholesterol is critical for infection by many viruses
(23, 26, 40, 53, 73, 87). Indeed, components of the receptor
complex for dengue virus, another flavivirus, are reported to be
localized to cholesterol-enriched microdomains called lipid
rafts, such that depletion of cholesterol by methyl-$-cyclodex-
trin (M$CD) inhibits dengue virus entry (65). These choles-
terol-enriched microdomains serve as distinct domains on the
plasma membrane, where many cellular proteins, including
viral receptors, are preferentially localized. Examples of such
proteins include caveolins, flotillins, Shc, mitogen-activated
protein kinase, and protein kinase C (60). Localization to cho-
lesterol-enriched plasma membrane microdomains has been
demonstrated for both CD81 (18, 71) and SR-BI (66). SR-BI
has been reported to be localized in cholesterol-enriched
plasma membrane microdomains called caveolae (5, 35).
Cross-linking of CD81 and downstream Lck activation by HCV
sE2 are disrupted by M$CD in T cells (71), demonstrating a
functional role for localization of CD81 to cholesterol-en-
riched domains. Furthermore, CD81 has been demonstrated to
physically interact with cholesterol (17). While the dependence
of HCV infection on cellular cholesterol is currently unknown,
HCVpp fusion with liposomes is enhanced by the presence of
cholesterol in the target membrane (46). These data strongly
suggest that plasma membrane cholesterol may be required for
HCV entry.
In the current study, we used the recently reported in vitro
JFH-1 HCV infection and HCVpp viral systems and antibodies
specific for CD81 and SR-BI to demonstrate that CD81 and
SR-BI function cooperatively to mediate HCV infection in
Huh-7 cells. The depletion of membrane cholesterol using the
cholesterol-depleting drug M$CD decreases HCV infection, in
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part by causing the mislocalization and decreased surface ex-
pression of CD81.
MATERIALS AND METHODS
Tissue culture and generation of stable HCV subgenomic replicon cell lines.
The JFH-1 (genotype 2a) subgenomic HCV replicon was obtained from Takaji
Wakita (Tokyo Metropolitan Institute of Neuroscience, Tokyo, Japan) and pas-
saged as previously described (27, 43, 44). HCV replicon-containing and parental
Huh-7 cells were cultured in complete Dulbecco’s modified Eagle’s medium
(DMEM) (supplemented with 10% fetal calf serum [FCS], 100 U/ml penicillin,
100 mg/ml streptomycin, 2 mM L-glutamine, and 0.1 mM nonessential amino
acids). The HCV replicon cell lines were cultured in the presence of 500 %g/ml
Geneticin (Invitrogen, San Diego, CA). Huh-7 cells were cultured as described
previously (41, 42, 92).
Generation of JFH-1 virus stocks and infections. JFH-1 virus stocks were
generated by infecting Huh-7.5.1 cells as described previously (92). The multi-
plicity of infection (MOI) was calculated based on JFH-1 titer as measured by
focus forming units/ml. For SR-BI and CD81 neutralization experiments, Huh-7
cells were pretreated with the respective antibodies as discussed below and
infected with JFH-1 at an MOI of 0.3 in a volume of 50 %l complete DMEM. The
virus inoculum was incubated with cells for 5 h, after which cells were washed
twice with phosphate-buffered saline (PBS) and incubated with complete
DMEM for the duration of the experiment. For all experiments involving de-
pletion of cellular cholesterol by M$CD, infections were performed using an
MOI of 0.02.
RNA extractions, reverse transcription, and real-time PCR analysis. Total
RNA was isolated using guanidine thiocyanate extraction as described previously
(20). Reverse transcription (RT) reactions and real-time PCR analyses were
performed as previously described (42, 92).
HCV neutralization assays. Virus neutralization assays were performed as
previously described (92). Antibodies directed against the extracellular loop of
SR-BI were raised by genetic immunization of Wistar rats with a pcDNA ex-
pression vector containing the full-length human SR-BI cDNA (pcDNA SR-BI/
CLA-1; a gift from T. Huby, INSERM, Dyslipoproteinemia and Atherosclerosis
Research Unit, Hopital de la Pitie´, Paris, France). Briefly, rats received four
injections of 20 %g pcDNA SR-BI intraperitoneally at 2-week intervals. Preim-
mune control serum was collected from the same rat bled before immunization.
To analyze the specificity of the produced anti-SR-BI polyclonal serum, CHO
cells were transfected with pcDNA (control vector) or pcDNA SR-BI using
liposome-mediated gene transfer (Lipofectamine; Invitrogen, Karlsruhe, Ger-
many) according to the manufacturer’s protocol. CHO cells were then incubated
with anti-SR-BI polyclonal serum or preimmune control serum and analyzed for
cell surface SR-BI expression by flow cytometry as described previously (7).
Huh-7 cells (5 & 103/well) were seeded into 96-well plates (Corning Inc., Corn-
ing, NY), and the following day, cells were incubated with dilutions of antibodies
specific for SR-BI or CD81 (5A6 clone; a gift from Shoshana Levy, Stanford
University, Stanford, CA) for 1 h at 37°C. Cells were then infected with JFH-1
at an MOI of 0.3, and intracellular JFH-1 RNA and NS5A protein expression
levels were monitored by RT-PCR and indirect immunofluorescence, respec-
tively, 3 days later, as previously described (92). We define an effect of both
antibodies as synergistic or cooperative if the change (n-fold) when using the
two antibodies is equal to or greater than that of the product rather than the
sum of the changes (n-fold) of HCV RNA replication detected when using
the antibodies individually.
Cholesterol depletion experiments. M$CD and cholesterol were obtained
from Sigma (St. Louis, MO). Huh-7 cells (105/well) were seeded into 12-well
BioCoat plates (BioCoat, Horsham, PA). The next day, cells were washed with
PBS and incubated with 7.5 mM M$CD in incomplete DMEM (without FCS) for
30 min at 37°C. Cells were washed with PBS and then incubated in incomplete
DMEM alone or containing 150 %g/ml cholesterol (to replenish cholesterol
levels) for 1 hour at 37°C. Huh-7 cells were washed twice with PBS and then
infected with JFH-1 virus at an MOI of 0.02 in DMEM containing 5% FCS. At
various times postinfection, total RNA was isolated for RT-PCR analysis. M$CD
treatment of preinfected Huh-7 cells or JFH-1 subgenomic (JFH-1 SG) replicon-
containing cell lines was performed in a similar manner.
HCVpp generation and infection. All pseudoviruses were generated by co-
transfection of plasmids encoding (i) a provirus containing the desired reporter
gene or transgene, (ii) human immunodeficiency virus (HIV) Gag-Pol, and (iii)
an appropriate envelope glycoprotein. All HCVpp used in this study were gen-
erated using the H77 E1E2 sequence (residues 170 to 746). On the day prior to
transfection, 8 & 105 293T cells were seeded in a 35-mm well. The following day,
a total of 1.5 %g DNA was transfected using Lipofectamine (Invitrogen, Carls-
bad, CA). The media were replaced after 6 h. Supernatants were harvested at 48
and 72 h posttransfection, pooled, and filtered using a 0.45-%m-pore-size filter.
The plasmid combinations and ratios (by weight) used to generate luciferase
reporter HCVpp are listed below. Equal amounts of pNL43.luc.R-.E- (encoding
a provirus containing luciferase and HIV Gag-Pol) and plasmids expressing
HCV E1E2, murine leukemia virus (MLV) Env, and empty vector were cotrans-
fected, giving rise to HCVpp, MLVpp, and “no envelope” pseudoparticles,
respectively, as previously reported (39). To generate green fluorescent protein
(GFP) reporter HCVpp, plasmids encoding (i) an HIV provirus encoding GFP
(12), (ii) HIV Gag-Pol, and (iii) H77 E1E2 or empty vector were transfected at
a 1:1:4 ratio. Infection assays with luciferase reporter HCVpp were performed in
a 96-well format using 104 target cells per well. Cells were infected with pseudovi-
rus supernatants diluted in fresh media (1:5 for HCVpp and “no Env” pp; 1:500
for MLVpp). After 8 h, the media were changed and luciferase assays were
performed at 72 h postinfection as previously described (7). Briefly, cells were
lysed with 40 %l cell culture lysis (Promega, Madison, WI) and the expression of
the luciferase reporter was measured after the addition of 50 %l luciferase
substrate (Promega, Madison, WI) on a Centro LB960 luminometer (Berthold
Technologies, Bad Wildbad, Germany). For infection assays with the GFP re-
porter, 3& 104 HCVpp were plated in 48-well plates. The next day, the cells were
infected with pseudovirus for 8 h, the media were changed, and cells were further
cultured for an additional 48 h prior to harvesting and fixation with 1% (wt/vol)
paraformaldehyde. GFP expression was quantified using a FACSCalibur flow
cytometer (Becton Dickinson, Franklin Lakes, NJ).
Indirect immunofluorescence staining of CD81. The protocol for indirect
immunofluorescence has been described previously (41, 92). Briefly, 3 & 104
Huh-7 cells were seeded into Lab-Tek eight-chamber coverglasses (Nalge Nunc
International, Naperville, IL). The next day, the cells were treated with M$CD
as described above. After treatment, Huh-7 cells were fixed with 4% paraform-
aldehyde for 20 min at room temperature and stained for CD81 expression by
indirect immunofluorescence analysis. Cells were incubated with antibodies spe-
cific to CD81 (5A6 clone; a gift from Shoshana Levy, Stanford University,
Stanford, CA) at a dilution of 1:100, followed by incubation with a secondary
antibody conjugated to Alexa 555 fluorochrome (Invitrogen Corporation, Carls-
bad, CA). Serial Z sections were analyzed using a deconvolution microscope as
described previously (41).
Flow cytometric analysis of cell surface CD81 and SR-BI. Huh-7 cells (8 &
105) were seeded into 60-mm dishes (Corning Inc., Corning, NY). The next day,
cells were treated with M$CD as described above, trypsinized, and resuspended
in staining buffer (1% bovine serum albumin in PBS). Cells were incubated with
antibodies specific for CD81 (Serotec, Raleigh, NC) or SR-BI (Novus Biologi-
cals, Littleton, CO) at dilutions of 1:100 for 30 min at 4°C. Incubation without
primary antibodies gave no specific staining. Cells were washed three times with
staining buffer and incubated with donkey anti-mouse (CD81) or anti-rabbit
(SR-BI) antibody conjugated to phycoerythrin (Santa Cruz Biotechnology, Santa
Cruz, CA) at a 1:100 dilution for 30 min at 4°C. Cells were washed three times,
fixed in 2% paraformaldehyde, and analyzed by flow cytometry using a Becton
Dickinson FACSArray. A total of 50,000 events were collected per sample. Mean
fluorescence intensities (MFI) were measured by calculating the geometric mean
for each histogram peak.
Quantitation of intracellular cholesterol levels. Huh-7 cells (8 & 105/well)
were seeded in 12-well plates (Corning Inc., Corning, NY). The next day, cells
were treated with 7.5 mM M$CD as described above. The cells were washed
twice with PBS, counted, and lysed in PBS containing 1% Triton X-100. Lysates
generated from 4 & 105 Huh-7 cells were spun at 20,000 & g for 5 min to remove
debris, and cholesterol levels were quantitated using an Amplex Red cholesterol
assay kit (Molecular Probes, Eugene, OR) as per the manufacturer’s recommen-
dations. Fluorescence was measured using TECAN Safire II (Tecan Systems Inc.,
San Jose, CA). A standard curve using purified cholesterol was generated for
each experiment.
Statistical analyses. All statistical analyses were performed using Microsoft
Excel software. All graphs represent means ' standard deviations (SDs). P values
for all data were determined using the paired t test.
RESULTS
CD81 and SR-BI are required for HCV infection. To deter-
mine whether CD81 and SR-BI are required for HCV infec-
tion, we infected Huh-7 human hepatoma cells with JFH-1
virus in the presence of antibodies specific for CD81 and SR-
BI, individually and together (92). As shown in Fig. 1A, incu-
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bation of Huh-7 cells with various concentrations of a mono-
clonal mouse anti-CD81 antibody resulted in a dose-
dependent inhibition of intracellular JFH-1 RNA at 3 days
postinfection ("17.8-fold [P ( 0.014] and "11.6-fold [P (
0.016] at 25- and 10-%g/ml antibody concentrations, respec-
tively). Similarly, the rat anti-SR-BI polyclonal antiserum re-
sulted in "8.6-fold (P ( 0.014) and "2.9-fold decreases in
intracellular JFH-1 RNA levels at 3 days postinfection at di-
lutions of 1:50 and 1:100, respectively (Fig. 1A). No significant
decrease in intracellular JFH-1 RNA was detected using either
isotype-matched mouse immunoglobulin G (IgG) or preim-
mune (PI) rat serum (Fig. 1A). The number of NS5A-positive
Huh-7 cells was also markedly decreased after incubation with
anti-CD81 (compare Fig. 2A and D) or anti-SR-BI (compare
Fig. 2A and E) antibody, consistent with the decrease in intra-
cellular JFH-1 RNA. No significant change in cell proliferation
was observed when the cells were incubated with either anti-
CD81 or anti-SR-BI antibody (data not shown).
Cooperation between SR-BI and CD81 is required for HCV
infection. To determine whether CD81 and SR-BI function
cooperatively to mediate HCV infection, Huh-7 cells were
incubated with concentrations of anti-CD81 (25 and 2.5 %g/ml)
and anti-SR-BI (1:50 and 1:100) antibodies and compared to
cells incubated with anti-CD81 or anti-SR-BI antibody alone.
While intracellular JFH-1 RNA levels were decreased "11.6-
fold or "8.6-fold when Huh-7 cells were incubated with 25
%g/ml anti-CD81 or a 1:50 dilution of anti-SR-BI, respectively,
coincubation of the Huh-7 cells with both anti-CD81 and anti-
SR-BI antibodies at the same concentrations resulted in a
significantly greater ("116.6-fold; P ( 0.012) decrease in in-
tracellular JFH-1 RNA (Fig. 1B). This cooperativity between
CD81 and SR-BI was also detected when Huh-7 cells were
incubated with a lower dilution (1:100) of the anti-SR-BI an-
tibody, which alone did not result in a statistically significant
decrease ("2-fold decrease; P ( 0.19) in intracellular JFH-1
RNA (Fig. 1B). Using 10-fold less anti-CD81 antibody (2.5
%g/ml), intracellular JFH-1 RNA was decreased "5.1-fold
(P ( 0.013). However, in combination with a 1:100 dilution of
anti-SR-BI antibody, intracellular JFH-1 RNA was decreased
"34-fold (P( 0.014) (Fig. 1B). Similarly, fewer NS5A-positive
Huh-7 cells were detected after coincubation with both anti-
CD81 (25 %g/ml) and anti-SR-BI (1:50) antibodies (Fig. 2F)
than when the cells were incubated with the antibodies indi-
vidually (Fig. 2D and E). No significant change in cell prolif-
FIG. 1. SR-BI is required for JFH-1 infection. Huh-7 cells were
incubated with anti-CD81 or anti-SR-BI antibody and inoculated with
JFH-1, and infectivity was analyzed by measuring intracellular JFH-1
RNA at 3 days postinfection. (A) Huh-7 cells were infected with JFH-1
in the presence of three dilutions each of anti-CD81 (250, 25, and 10
%g/ml) and anti-SR-BI (1:20, 1:50, and 1:100) antibodies. As controls,
Huh-7 cells were incubated with isotype-matched mouse IgG (mIgG)
and PI rat serum at 250-%g/ml and 1:50 dilutions, respectively.
(B) Huh-7 cells were incubated with concentrations of anti-CD81
antibodies alone (bars with horizontal lines), anti-SR-BI antibodies
alone (unfilled bars), or both antibodies (bars with diagonal lines), and
intracellular JFH-1 RNA levels were measured 3 days later. Two
dilutions each of anti-CD81 (25 and 2.5 %g/ml) and anti-SR-BI (1:50
and 1:100) antibodies were used. To demonstrate cooperativity, Huh-7
cells were incubated with combinations of anti-CD81 and anti-SR-BI
antibodies. Cells were incubated with anti-CD81 and anti-SR-BI anti-
bodies (25 %g/ml anti-CD81 plus 1:50 anti-SR-BI and 2.5 %g/ml anti-
CD81 plus 1:100 anti-SR-BI). As controls for anti-CD81 and anti-SR-BI
antibodies, Huh-7 cells were incubated with equivalent concentrations
of isotype-matched mouse IgG and PI rat serum, respectively. HCV
RNA copy numbers were normalized to GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) copy numbers for all samples. These are
representative data (means ' SDs) for three independent experi-
ments. (C) Inhibition of HCVpp entry using antibodies specific to
CD81 (25 mg/ml) and SR-BI (1:50) individually or in combination. TU,
transducing units. These are representative data (means ' SDs) for
three replicates.
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eration was observed when the cells were incubated with a
combination of anti-CD81 and anti-SR-BI antibodies. This
synergistic effect suggests that SR-BI and CD81 function co-
operatively during HCV infection, presumably at the level of
entry.
To study this further, we evaluated the ability of the anti-
CD81 and anti-SRBI antibodies, alone and in combination, to
neutralize HCVpp entry into Huh-7 cells. Antibodies to CD81
(25 %g/ml) and SR-BI (1:50) neutralized HCVpp infectivity
"5- and "2.1-fold, respectively, and "6.6-fold in combination
(Fig. 1C). Similar results were observed at lower antibody
concentrations (data not shown). These data suggest that while
both CD81 and SR-BI are required for HCVpp entry, they do
not function cooperatively in the HCVpp system.
M!CD decreases CD81 but increases SR-BI cell surface
expression. Since CD81 and SR-BI localize to specialized
plasma membrane microdomains that are enriched in choles-
terol (18, 66), we assessed whether depletion of cholesterol by
M$CD alters the membrane expression of CD81 and SR-BI.
Huh-7 cells were treated with M$CD, after which indirect
immunofluorescence staining was performed using antibodies
specific to CD81 and SR-BI. As shown in Fig. 3, M$CD treat-
ment decreased plasma membrane localization of CD81 (com-
pare Fig. 3A and B) and this could be reversed by the replen-
ishment of cholesterol (Fig. 3C). In contrast, M$CD treatment
did not appear to decrease SR-BI localization at the plasma
membrane (data not shown). To confirm these observations,
we used flow cytometric analysis to determine whether surface
expression of CD81 and SR-BI was altered by M$CD treat-
ment. Based on the MFI, M$CD treatment of Huh-7 cells
resulted in an "2.5-fold decrease in cell surface expression of
CD81 (Fig. 4A and C). Interestingly, cell surface expression of
SR-BI was increased "2.4-fold (Fig. 4B). Furthermore, the
changes in cell surface expression of CD81 (Fig. 4A) and
SR-BI (Fig. 4B) were reversed when M$CD-treated cells were
incubated with exogenous cholesterol. These results demon-
strate that while depletion of cholesterol by M$CD results in a
decrease of cell surface CD81 expression, SR-BI expression
levels are induced after cholesterol depletion.
M!CD depletion of cholesterol from Huh-7 cells inhibits
HCV infection. Since cholesterol depletion by M$CD led to a
decrease in cell surface expression levels of CD81, we deter-
mined whether cellular cholesterol depletion inhibits JFH-1
infection in vitro. Accordingly, Huh-7 cells were pretreated
with 7.5 mM M$CD and cholesterol was either added or not
added back to the culture medium prior to infection. Cells
were washed with PBS to remove M$CD and/or cholesterol
before the cells were infected with JFH-1 at an MOI of 0.02.
Infection of Huh-7 cells pretreated with M$CD resulted in an
"6.2-fold decrease in intracellular JFH-1 RNA at 3 days
postinfection (P ( 0.03) (Fig. 5A). This decrease in JFH-1
RNA was reversed when M$CD-treated Huh-7 cells were in-
cubated with exogenous cholesterol prior to infection (Fig.
5A), suggesting that the reduction in JFH-1 RNA is due to
cellular cholesterol depletion. In order to determine whether
M$CD treatment depletes cellular cholesterol levels, we quan-
titated the amount of cellular cholesterol before and after
M$CD treatment. M$CD-treated Huh-7 cells reduced the to-
tal intracellular pools of cholesterol by "60% (P ( 0.001)
compared to mock-treated cells (Fig. 5B). Huh-7 cells treated
FIG. 2. Anti-SR-BI antibodies inhibit JFH-1 NS5A protein expression. Indirect immunofluorescence analysis of NS5A protein expressed in
JFH-1-infected Huh-7 cells alone (A) or in the presence of anti-CD81 (25 %g/ml) (D), anti-SR-BI (1:50) (E), or a combination of both anti-CD81
and anti-SR-BI antibodies (F). Huh-7 cells were incubated with equivalent concentrations of isotype-matched mouse IgG (mIgG) (B) and PI rat
serum (C) as controls for the anti-CD81 and anti-SR-BI antibodies, respectively. The bars represent 400-%m distances. These are representative
data for three independent experiments.
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with an inactive stereoisomer of M$CD, )-cyclodextrin (80),
had no effect on intracellular JFH-1 RNA levels (data not
shown). To determine whether M$CD treatment affected
Huh-7 growth, we quantitated the number of viable Huh-7
cells at various times posttreatment by trypan blue exclusion.
As can be seen in Fig. 5C, there was no significant change in
the total number of viable Huh-7 cells during the course of the
infection. Altogether, these data demonstrate that HCV infec-
tion in vitro is dependent on the cholesterol content of the cell.
Cellular cholesterol depletion by M!CD does not affect
HCV replicon RNA replication. The decrease in intracellular
JFH-1 RNA content after M$CD pretreatment could be due
to an effect of M$CD either on JFH-1 RNA replication or on
JFH-1 viral entry. To determine whether M$CD treatment
affects HCV RNA replication, Huh-7 cells supporting replica-
tion of the JFH-1 SG replicon were treated with 7.5 mM
M$CD and intracellular levels of JFH-1 RNA were measured
at various times posttreatment. While treatment of JFH-1 SG
FIG. 3. M$CD treatment of Huh-7 cells decreases CD81 plasma membrane expression. CD81 expression was analyzed in mock-treated Huh-7
cells (A) or in Huh-7 cells after treatment with 10 mM M$CD (B). CD81 expression was also determined in M$CD-treated cells to which
exogenous cholesterol was added (C). SR-BI expression was also analyzed in mock-treated (D) and M$CD-treated (E) Huh-7 cells. The bars
represent 60-%m distances. These are representative data for at least two independent experiments.
FIG. 4. CD81 cell surface expression decreases after M$CD treatment. Cell surface expression of CD81 (A) and SR-BI (B) was analyzed in
mock-treated Huh-7 cells (M), Huh-7 cells that were treated with 10 mM M$CD (M$CD), or M$CD-treated cells which were further incubated
with cholesterol (M$CD!C). (C) MFI of CD81 surface expression after mock treatment or treatment with 10 mM M$CD in the presence
(M$CD!C) or absence (M$CD) of exogenous cholesterol are plotted. These are representative data for at least two independent experiments.
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replicon-containing cells with M$CD decreased levels of intra-
cellular cholesterol "2-fold (Fig. 6B), it failed to significantly
affect JFH-1 intracellular RNA levels at 2 days posttreatment
(Fig. 6A). Similar results were obtained using the genotype 1b
S1179I-adapted subgenomic replicon (data not shown).
Depletion of cholesterol by M!CD does not affect the re-
lease of infectious HCV from infected cultures. Since some
viruses require cholesterol for virion assembly and/or egress
from the cell (53–55, 57), we tested whether M$CD treatment
affects HCV RNA replication and virus production during an
ongoing JFH-1 infection. Huh-7 cells were infected with JFH-1
at an MOI of 0.02 for 9 days, by which time the majority of cells
are infected with JFH-1 (determined by NS5A immunofluo-
rescence staining) (data not shown) and secrete "103 to 104
focus-forming units/ml of infectious JFH-1 virus (day 0) (Fig.
6D). As shown in Fig. 6C, treatment of infected Huh-7 cells
with M$CD did not significantly suppress JFH-1 RNA repli-
cation, consistent with our results for the JFH-1 SG replicon-
containing cells (Fig. 6A). However, while M$CD treatment
reduced intracellular cholesterol levels by 68% (data not
shown), it failed to affect the secretion or infectivity of JFH-1
particles (Fig. 6D). These results suggest that HCV secretion is
not dependent on cellular levels of cholesterol.
HCVpp entry is dependent on cellular cholesterol. To spe-
cifically determine whether cholesterol depletion by M$CD
inhibits HCV entry, we utilized the HCVpp system, which has
been used extensively to address the molecular mechanisms of
HCV entry into cells (9, 10, 16, 34, 46, 81, 83). Huh-7 cells were
pretreated with M$CD in the presence or absence of supple-
mentary cholesterol in the culture medium. The cells were
infected with pseudotype particles expressing either HCV gly-
coproteins (HCVpp) or murine leukemia virus glycoproteins
(MLVpp), and luciferase was quantitated at 72 h postinfection.
As shown in Fig. 7A, there was a dose-dependent inhibition of
HCVpp entry. Pretreatment of Huh-7 cells with 10 mM M$CD
resulted in an "50% reduction (P ( 0.007) of HCVpp entry
(Fig. 7B). This inhibition could be reversed by the replenish-
ment of cholesterol in the M$CD-treated cells prior to infec-
tion with HCVpp (Fig. 7). In comparison, entry of MLVpp was
not significantly affected (P ( 0.1) by the depletion of choles-
terol (Fig. 7). Collectively, these data demonstrate that the
cholesterol content of the cell influences the efficiency of viral
entry during HCV infection.
DISCUSSION
The results reported herein demonstrate that SR-BI and
CD81 function cooperatively to mediate HCV infection in
vitro and indicate that cellular cholesterol is required for effi-
cient HCV infection in vitro, most likely due to the effects of
cholesterol on the cell surface expression level of CD81. The
differences in the neutralizing activity of the anti-CD81 and
anti-SRBI antibodies for HCVpp and infectious JFH-1 virus
suggest that there are important differences in the mechanisms
of action of the antibodies in the two viral systems. Anti-CD81
and anti-SRBI antibodies neutralize HCVpp entry but fail to
show any synergistic effects in combination, suggesting that the
cooperativity observed for inhibiting the initiation of JFH-1
infection may occur at a postentry level. Several reports have
demonstrated an SR-BI-dependent activation of phosphatidyl-
inositol 3-kinase (51, 69), where antibody engagement of
SR-BI may activate signaling pathways that JFH-1 virus may
utilize postentry. Furthermore, the mechanism by which SR-BI
mediates HCV entry is not completely understood. While sE2
has been shown to bind SR-BI (7, 68), it has not been techni-
cally feasible to determine whether E1E2 glycoprotein het-
erodimers bind SR-BI. However, von Hahn et al. recently
demonstrated that oxidized LDL, which is a natural ligand for
SR-BI, can inhibit HCVpp and HCV infection, supporting a
critical role for SR-BI in HCV entry (84). Furthermore, Heo
FIG. 5. Depletion of cholesterol by M$CD decreases JFH-1 infec-
tion in Huh-7 cells. Huh-7 cells were untreated or pretreated with 7.5
mM M$CD alone (M$CD) or M$CD plus cholesterol (M$CD ! C)
prior to infection with JFH-1. (A) Total RNA was harvested 3 days
later, and levels of intracellular JFH-1 RNA were quantitated by RT-
PCR. Relative HCV levels were measured by normalization to
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) copy numbers
for each sample. (B) Intracellular cholesterol levels were quantitated
in mock-treated Huh-7 cells or cells that were treated with M$CD
alone (M$CD) or M$CD plus cholesterol (M$CD ! C). (C) Viable
cells were quantitated by trypan blue exclusion after M$CD treatment
(in the absence or presence of cholesterol) and compared to mock-
treated Huh-7 cells.
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et al. recently demonstrated that HCV E2 glycoprotein links
soluble CD81 and SR-BI protein together (38). HCV in
plasma from infected patients has been reported to associate
with very-low-density lipoprotein (VLDL) and LDL (1, 4, 56,
75, 76), and a recent report suggests that virus-lipoprotein
complexes interact with cells via SR-BI (49). Another candi-
date receptor for HCV, the LDL-R, has been reported to
internalize plasma-derived virus by interacting with LDL and
VLDL complexed with HCV particles (1, 4, 52). The LDL-R is
responsible for binding and uptake of apolipoproteins B
(ApoB0) and E (ApoE) (28), and since ApoB and ApoE have
been demonstrated to be associated with HCV in the sera of
infected patients (56), this has led to the suggestion that the
LDL-R may internalize virus through binding of virion-associ-
ated lipoproteins. However, the experimental evidence to sup-
port a role of the LDL-R in HCV entry is lacking. Interest-
ingly, oxidized low-density lipoprotein, a ligand for SR-BI, was
shown to inhibit HCVpp and HCV infection (84). Since SR-BI
can interact with HDL, VLDL, and native and chemically
modified LDL (77), these results suggest that SR-BI may bind
HCV particles through interactions with apolipoproteins. In-
terestingly, HDL was recently demonstrated to facilitate SR-
BI-mediated HCVpp entry (81) and also decrease antibody-
mediated neutralization of HCV (29, 82).
The current results demonstrate that HCV infection is de-
pendent on the cholesterol content of the cell. Depletion of
cholesterol from cellular membranes by M$CD has been dem-
onstrated to inhibit infection by many viruses (19, 26, 63, 70).
However, the extent to which flavivirus infections are sensitive
to cellular cholesterol levels is still unclear. While infection by
dengue virus is markedly inhibited by cholesterol depletion
(65), infection by another flavivirus, tick-borne encephalitis
virus, is only modestly affected (72). Our results demonstrate
that depletion of cellular cholesterol by M$CD suppresses
JFH-1 infection (Fig. 5A) and HCVpp entry (Fig. 7). However,
the inhibition is incomplete and may reflect the partial deple-
tion of cholesterol from plasma membranes. While many fla-
viviruses, including HCV, utilize clathrin-dependent receptor-
mediated endocytosis to enter cells (13, 21, 22, 24, 36), other
viruses enter cells through caveolae (58). Both caveolae and
clathrin structures are specialized plasma membrane domains
that are enriched in cholesterol, and both are disrupted by the
depletion of cholesterol (45, 59). While membrane cholesterol
may be directly required for receptor expression and/or local-
ization to initiate HCV infection, it is possible that cholesterol
is required for additional plasma membrane-associated pro-
tein-protein interactions that regulate the initiation of HCV
infection. Alternatively, it is possible that HCV may utilize
mechanisms for entry that do not depend solely on cellular
membrane cholesterol levels, since cholesterol depletion does
not completely inhibit HCV infection (Fig. 5A) or HCVpp
entry (Fig. 7).
In contrast to its effect on CD81, M$CD depletion of cho-
lesterol increases cell surface expression of SR-BI (Fig. 4B).
FIG. 6. Depletion of cholesterol by M$CD does not affect HCV RNA replication. (A) Huh-7 cells stably replicating the JFH-1 SG replicon
were treated with 7.5 mM M$CD, and intracellular levels of JFH-1 RNA were measured at 1 and 2 days posttreatment. (B) Intracellular
cholesterol levels in Huh-7 cells were quantitated after treatment with M$CD (M$CD) or M$CD plus cholesterol (M$CD!C). (C and D) Huh-7
cells were infected with JFH-1 for 9 days, after which cells were untreated or treated with 7.5 mM M$CD (M$CD) or M$CD plus cholesterol
(M$CD!C). Intracellular JFH-1 RNA levels (C) and JFH-1 virus secretion (D) were quantitated before the start of treatment (day 0) and at 2
days posttreatment. These are representative data (means ' SDs) for three independent experiments. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; ffu, focus-forming units.
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These results are consistent with published data demonstrating
that SR-BI mRNA and protein levels are increased after
M$CD-mediated depletion of cholesterol (37, 74, 90). While
our results suggest that the initial steps of HCV infection are
dependent partially on membrane cholesterol, this could re-
flect a compensatory increase in SR-BI membrane expression
in the context of reduced CD81 expression induced by choles-
terol depletion. Since JFH-1 infection is inhibited under these
circumstances, this may suggest that the SR-BI dependence of
HCV infection may be secondary to CD81. This is supported
by the observations that CD81-blocking antibodies strongly
inhibit HCVpp entry (11) and that HepG2 cells, which express
SR-BI but not CD81, are not permissive for HCVpp infection
(11). On the other hand, these results could also be explained
by the different levels of cell surface SR-BI and CD81 required
for HCV infection.
In conclusion, we have demonstrated that HCV infection is
dependent on a cooperative interaction between CD81 and
SR-BI and that cellular cholesterol content has a significant
impact on HCV entry, possibly by regulating cell surface ex-
pression and localization of CD81. Recent data suggest that
HCV infectivity is dependent upon the density of SR-BI and
CD81 in the target cell and that threshold amounts are re-
quired for efficient infection (A. E. Jennings, Z. Stamataki, J.
Grove, P. Balfe, and J. A. McKeating, unpublished data).
These results favor the existence of a multicomponent recep-
tor-mediated mechanism of HCV entry in which CD81 and
SR-BI play essential but different roles in the internalization of
HCV. The results add to the growing knowledge of the impor-
tance of cholesterol and its synthesis in HCV infection and
pathogenesis.
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